Dianthus Therapeutics(NASDAQ) DNTH

Dianthus makes medicines for people with serious immune system problems. These special proteins help stop the body from attacking healthy tissue. The treatments are designed for easy use at home.

Fighting the Body's Own Attack

• Claseprubart: A human antibody targeting the C1s protein to stop harmful immune chain reactions; designed for self-administered injections.
• DNTH212: A dual-action protein that blocks two different pathways to reduce immune activity; currently in early clinical testing.
• Pipeline Candidates: Research programs focusing on other complement proteins to expand treatments for rare inflammatory conditions.

Building a Biotech Powerhouse

• Magenta Therapeutics: Completed a reverse merger in September 2023 to become a publicly traded company.
• Nanjing Leads Biolabs: Signed a licensing deal in October 2025 to develop a new protein globally outside of Greater China.
• Tenacia Biotechnology: Partnered in October 2024 to develop and sell specific treatments in the Chinese market.
• Zenas BioPharma: Initially partnered for antibody development before the agreement moved to an affiliate in 2024.

What Makes Dianthus Different

The company uses special half-life extension technology so patients need fewer injections over time. Their treatments only target active parts of the immune system to lower the risk of infection.

Checking the Books

• Revenue was $463,000 in Q1 2026, down 60% from $1.2 million in Q1 2025.
• Net loss reached $40.8 million in Q1 2026, which worsened by 38% compared to the previous year.
• Total current assets hit $1.12 billion as of March 31, 2026, following a major public offering.
• Operating expenses rose to $47 million in Q1 2026 from $34.3 million in Q1 2025.

The Final Word

Dianthus has transitioned into a well-funded clinical stage company through strategic mergers and large capital raises. Its focus on user-friendly injections for complex diseases defines its current development path.